First AD

Second AD

CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel   

Dr. Jabbour to Dr. Muffly: What is the general mechanism of CAR T-cell therapy? What are the differences between the various CAR-Ts Brexucabtageneautoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtageneautoleucel (Obe-cel)?

Brexu-cel & Tisa-cel CAR-T Construct Design

Obe-Cel CAT19-41BB-Z Fast Off Rate Design

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia  

Peer Exchange

Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel). 